HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients.

Abstract
Management of secondary hyperparathyroidism is difficult because of the interrelationship of parathyroid hormone, calcium and phosphorus. This study was carried out to assess the efficacy of intravenous administration of alfacalcidol once weekly versus twice weekly in patients with severe hyperparathyroidism. Twenty-one hemodialysis patients with intact parathyroid hormone >88 pmol/L were divided into two groups. Eleven patients (Group 1) were given a once-weekly alfacalcidol intravenously for 12 weeks. The starting dose was 4 microg which was increased or decreased by 1 microg per week. Ten patients (Group 2) were given twice-weekly alfacalcidol intravenously for 12 weeks. The starting dose was 2 microg twice weekly which was increased or decreased by 0.5 microg/dose. The dose was increased or decreased according to serum calcium and phosphorus levels. Serum calcium, phosphorus and alkaline phosphatase levels were measured weekly and intact parathyroid hormone every 4 weeks. Intact parathyroid hormone reduced significantly (P = 0.0001) from 128.12 +/- 35.42 pmol/L to 82.93 +/- 65.20 pmol/L and from 113.74 +/- 40.83 pmol/L to 64.24 +/- 35.17 pmol/L after 4 weeks in Groups 1 and 2, respectively. After 4 weeks alkaline phosphatase declined significantly (P = 0.0001) from 146.0 +/- 57.3 IU/L to 116.0 +/- 45.6 IU/L in Group 1 and from 139.0 +/- 45.1 IU/L to 116.6 +/- 38 IU/L in Group 2. There were no significant differences in serum levels of calcium, phosphorous or their product. Interestingly, an adenoma disappeared in one patient from Group 1, and out of two adenomas, one disappeared from another patient in the same group. These results indicate that intravenous alfacalcidol once weekly is safe and effective in suppressing high parathyroid hormone in hemodialysis patients.
AuthorsNabieh Al-Hilali, Hani Al-Humoud, Bassam Al-Helal, Mohammed Al-Azmi, Nasser H Al-Kandari, Kaivilayil V Johny
JournalTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 12 Issue 2 Pg. 137-42 (Apr 2008) ISSN: 1744-9987 [Electronic] Australia
PMID18387162 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Bone Density Conservation Agents
  • Hydroxycholecalciferols
  • Parathyroid Hormone
  • Phosphorus
  • Alkaline Phosphatase
  • Calcium
  • alfacalcidol
Topics
  • Adenoma (drug therapy)
  • Adult
  • Aged
  • Alkaline Phosphatase (blood)
  • Bone Density Conservation Agents (administration & dosage, adverse effects)
  • Calcium (blood)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Hydroxycholecalciferols (administration & dosage, adverse effects)
  • Hyperparathyroidism, Secondary (drug therapy, etiology)
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Parathyroid Hormone (blood)
  • Phosphorus (blood)
  • Prospective Studies
  • Renal Dialysis
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: